By Darrin LaVelle, Founder of RENVA Health
Last updated: July 4, 2026
Short answer: brand-name GLP-1 medications like Wegovy and Zepbound go through full FDA review for safety, effectiveness, and manufacturing quality before they're sold. Compounded versions don't — they're prepared by pharmacies under a separate legal framework that exempts them from that review entirely. That's a meaningful legal and safety distinction, not just a pricing difference.
If you've seen compounded semaglutide or tirzepatide advertised at a lower price than the brand-name version, it's worth understanding exactly what "compounded" means here — because the difference goes well beyond cost.
Pharmacy compounding is a long-established, legal practice: a licensed pharmacist or physician prepares a customized medication for an individual patient, typically because an FDA-approved product doesn't meet that specific patient's needs — for example, an allergy to an inactive ingredient, or a need for a different strength or form than what's commercially available. This isn't inherently sketchy or new; compounding has existed for a long time and serves a real medical purpose in the right circumstances.
Compounding falls under two distinct legal categories:
503A pharmaciesare state-licensed and compound based on a specific prescription for a specific patient. They're exempt from certain FDA requirements — like the new-drug-approval process and standard labeling rules — as long as they meet specific conditions, including that what they're making isn't "essentially a copy" of a commercially available drug.
503B outsourcing facilitiesregister with the FDA and can compound in larger batches without a patient-specific prescription. They're required to follow current good manufacturing practices, and the FDA can inspect their facilities. They're permitted to use bulk drug ingredients only under specific conditions — generally, when the drug is on an official shortage list or the ingredient is on an approved list of substances for compounding.
Neither category means the FDA has approved the resulting product. That's a critical point: the FDA doesn't "approve" pharmacies or compounded products at all — it approves specific drugs made by specific manufacturers, and compounded medications, by definition, fall outside that approval process.
When the FDA approves a drug like Wegovy, Zepbound, Foundayo, or Saxenda, that approval reflects a review of clinical trial data on safety and effectiveness, along with a review of the manufacturing process itself, to confirm the drug is made consistently and correctly every time.
Compounded products skip this entire process. In the FDA's own words: "Compounded drugs are not FDA-approved. This means FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed." That's not a technicality — it means no independent body has verified that a given compounded product actually contains what it claims, in the amount it claims, made under conditions that ensure consistency from batch to batch.
For a period, compounded semaglutide and tirzepatide became widely available specifically because both drugs experienced genuine, documented shortages. Under FDA rules, compounding a copy of an approved drug is permitted during a declared shortage, since patients need access to treatment that isn't otherwise available.
That justification has largely expired. As of 2026, semaglutide shortages have mostly resolved, which removes the legal basis for pharmacies to compound semaglutide copies from bulk ingredients simply because it's cheaper or more available than the brand-name product. Tirzepatide supply has been more variable, but the same principle applies: once a shortage ends, the legal justification for shortage-based compounding ends with it. The FDA has explicitly reminded compounders of this distinction, emphasizing that compounding a drug just because it's less expensive, without a shortage or documented individual patient need, doesn't meet the legal bar.
The FDA has been direct about the specific problems it's identified with compounded GLP-1 products, and it's worth knowing what these actually are rather than treating "compounded" as a vague catch-all concern:
Some compounders have used forms like "semaglutide sodium" or other salt forms that are chemically different from the active ingredient in FDA-approved semaglutide products — despite being marketed as equivalent.
The FDA has documented cases of patients receiving doses many times higher than intended, often due to confusing syringe units or inaccurate labeling on compounded vials — a real, documented safety issue distinct from any side effect of the drug itself.
Some products have used branding that implies manufacture or approval by the original drug maker, or claimed to contain "the same active ingredient as Ozempic/Wegovy/Mounjaro" without evidence supporting that claim.
Some marketing has described a pharmacy itself as "FDA-approved" — which the FDA has stated plainly is not a real designation, since the agency approves drugs, not pharmacies.
Separate FDA warning letters and safety assessments have identified compounded semaglutide products with incorrect potency and sterility violations — meaning the product wasn't manufactured under conditions that reliably prevent contamination.
The FDA has significantly increased enforcement against problematic compounded GLP-1 marketing in 2026. In February, the agency issued warning letters to around 30 telehealth and compounding operations over false or misleading claims — including claims of equivalence to approved products and language obscuring where a product actually came from. A second batch of roughly 25 warning letters followed in June, again targeting misleading branding and "FDA-approved pharmacy" language.
Separately, in April 2026, the FDA issued a clarification statement reminding both 503A pharmacies and 503B outsourcing facilities that the legal exemptions allowing compounding only apply when specific conditions are actually met — reinforcing that "cheaper" or "more available" isn't, on its own, a legal justification for compounding a copy of an approved drug.
The overall direction is clear: both the FDA and professional medical societies are actively steering routine obesity care toward FDA-approved brand-name medications, reserving compounding for genuinely justified individual cases rather than routine cost-driven alternatives.
There isn't much direct, peer-reviewed research comparing clinical outcomes between compounded and brand-name semaglutide or tirzepatide — most of the trial data you'll see referenced anywhere (including on this site) comes from studies of the FDA-approved products specifically. That's an important gap to be aware of: when you see weight-loss percentages from trials like STEP-1 or SURMOUNT-1, those results apply to the tested, FDA-approved formulation — not to compounded versions, which haven't been through the same trial process and may not be chemically identical.
Medical societies and obesity specialists generally recommend brand-name GLP-1 medications whenever they're available and accessible, reserving compounded versions for specific, well-documented situations — such as a genuine allergy to an inactive ingredient in the brand-name product — rather than as a routine lower-cost substitute.
If you're considering a compounded GLP-1 medication, whether through cost necessity or provider recommendation, it's worth getting specific answers to:
A provider or pharmacy unwilling or unable to answer these clearly is itself useful information.
Q: Is compounded semaglutide illegal?
Not inherently — compounding is a legal, regulated practice under specific conditions. What's illegal or against FDA guidance is compounding a copy of an approved drug outside those conditions (for instance, purely for cost reasons once a shortage has ended), or marketing a compounded product with false claims about its ingredients or approval status.
Q: Why is compounded semaglutide cheaper?
Compounded products skip the extensive (and expensive) clinical trial and FDA approval process that brand-name manufacturers go through, and they're often produced at smaller scale outside the same manufacturing infrastructure — both contribute to a lower price, but that price difference reflects the absence of the same regulatory review, not simply a markup on the brand-name product.
Q: Does "compounded" mean the medication doesn't work?
Not necessarily — but without FDA review, there's no independent verification that a specific compounded product contains the correct active ingredient, at the correct dose, made consistently batch to batch. The lack of that verification is the core concern, not a claim that compounded products universally don't work.
Q: How do I know if a provider is prescribing brand-name or compounded medication?
Ask directly. A transparent provider should clearly state whether they're prescribing an FDA-approved brand-name product or a compounded formulation, and should be willing to answer specific questions about the pharmacy and ingredient sourcing.
Q: Is compounded tirzepatide still legal given the ongoing supply fluctuations?
This depends on tirzepatide's current shortage status, which has fluctuated. Legal compounding based on a shortage is only valid while that shortage is officially in effect — worth verifying current status directly rather than assuming past availability still applies.
See also: How to Get Prescribed a GLP-1 Medication for the full evaluation and prescribing process, and Wegovy vs. Ozempic for how the FDA-approved semaglutide formulations compare to each other.
Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →
Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.
Take the free quizWhat it actually takes to get prescribed Wegovy, Zepbound, or another GLP-1 medication — eligibility criteria, the evaluation process, insurance steps, and realistic timelines.
Wegovy and Ozempic both contain semaglutide — but they're approved for different uses, dosed differently, and covered differently by insurance.
A clear look at GLP-1 side effects — from common nausea to rare but serious risks — based on FDA labeling and adverse event data, plus what tends to help.